Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
NCT07007962
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Immune Thrombocytopenia
Interventions
DRUG:
rilzabrutinib
Sponsor
Sanofi